Publications

2022

Hong, NH. et al. Advances in the Development of a Targeted N-Terminal Domain Androgen Receptor Degrader (ANITAC) for the Treatment of Prostate Cancer. Prostate Cancer Foundation (PCF) 2022 Scientific Retreat.
Read More > PCF 2022 Poster Presentation
Laccetti, A. et al. Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Preliminary Results from the Phase 1 (P1) Dose-optimization Component of the Study. Prostate Cancer Foundation (PCF) 2022 Scientific Retreat.
Read More > PCF 2022 Poster Presentation
Laccetti, A. et al. Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer: Results From the First-in-Human Dose Escalation Phase 1a Study. Prostate Cancer Foundation (PCF) 2022 Scientific Retreat.
Read More > PCF 2022 Poster Presentation
Hong, NH. et al. Androgen receptor (AR) N-Terminal Domain degraders can degrade AR full length and AR splice variants in CRPC preclinical models. 2022 American Association for Cancer Research (AACR) Annual Meeting.
Read More > AACR 2022 Poster Presentation

Hong, NH. et al. Comprehensive preclinical characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor. 2021 Prostate Cancer Foundation (PCF) Annual Scientific Retreat.
Read More > PCF 2021 Poster Presentation